The intervention group showed significant reductions in FPG, 2h PG, postprandial insulin, and central obesity after six months compared to baseline. Lower HbA1c, triglyceride/HDL ratio, and diabetes incidence were observed compared to the control group. Benefits persisted at the 12-month follow-up. This evidence concerns the gene INS and Abdominal obesity.